

# C. elegans ND Models (CRCHUM – Université de Montreal)

<https://neurodegenerationresearch.eu/survey/c-elegans-nd-models-crchum-universite-de-montreal/>

## **Name of Resource**

C. elegans ND Models (CRCHUM - Université de Montreal)

## **Name of Principal Investigator - Title**

Dr

## **Name of Principal Investigator - First name**

Alex

## **Name of Principal Investigator - Last name**

Parker

## **Address of institution -Institution**

CRCHUM - Université de Montreal

## **Address of institution - Street address**

## **Address of institution - City**

Montreal

## **Address of institution - Postcode**

## **Country**

Canada

## **Website**

<https://sites.google.com/site/jalexparker/welcome>

## **Contact email**

[ja.parker@umontreal.ca](mailto:ja.parker@umontreal.ca)

## **Summary**

C. elegans models of neurodegeneration

**Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions? (1)**

Motor neurone diseases| Alzheimer's disease and other dementias| Neurodegenerative disease in general

**Q1b. Does your resource hold**

Animals| Genetic Material (e.g. DNA, RNA, vectors)

**Q2a. Does the resource act as a centre for access and distribution to external groups (who are not the Principal Investigators (PI) for the resource)?**

Yes

**Q2b. If Yes, what procedures and rules apply for access?**

Apply to PI or co-ordinator at resource| Access independent of collaboration with PI

**Q3a. Does your resource develop experimental models (animal/cell) for external groups?**

Yes

**Q3b. If YES and your resource is related to an ANIMAL model, what types of models are provided?**

Wild type| Genetically Modified| Humanised

**Q3c. If YES and your resource is related to a CELL model, what types of models are provided?**

**Q4a. Is this activity supported as:**

**Q4b. Do you deposit what you supply in any kind of central repository?**

Disease

ALS| HD| PD

**Species**

C.elegans| C.elegans| C.elegans

**Available to external user**

Yes| No| No

**Full phenotypic character**

Yes| Yes| Yes

**Please indicate the phenotypes**

Motor neuron degeneration| Neuronal dysfunction| Dopaminergic neuron degeneration

**List of genotypes or other subtypes**

**Q5b. Cognitive function, No of models**  
**Q5b. Cognitive function, Available to external users**  
**Q5b. Cognitive function, Full phenotypic characterisation**  
**Q5b. Cognitive function, Nature of phenotype**  
**Q5b. Motor function, No of models**

5

**Q5b. Motor function, Available to external users**

Yes

**Q5b. Motor function, Full phenotypic characterisation**

Yes

**Q5b. Motor function, Nature of phenotype**

Degenerating motor neurons

**Q5b. Physiological function, no of models**  
**Q5b. Physiological function, Available to external users**  
**Q5b. Physiological function, Full phenotypic characterisation**  
**Q5b. Physiological function, Nature of phenotype**  
**Q5b. Other function (please specify), no of models**  
**Please specify other function**  
**Q5b. Other function (please specify), Available to external users**  
**Q5b. Other function (please specify), Full phenotypic characterisation**  
**Q5b. Other function (please specify), Nature of phenotype**  
**Q6. Please indicate if your resource is already linked into European or international consortia or networks?**  
**Q7a. Is maintenance of this resource dependent on continued funding?**

No

**Q7b. If yes, when does the current funding period end?**

**Q7c. What is the expected lifespan of the resource (in years)?**

Indefinite, can be frozen

**Q7d. Are there other plans affecting future use that it may be useful to know?**

**Types:**

Experimental Models

**Member States:**

Canada

**Diseases:**

N/A

**Years:**

2016

**Database Categories:**

N/A

**Database Tags:**

N/A